{"ok":true,"nota":{"id":"39f08b7cd8ec9ef4","slug":"medir-mas-tumores-en-el-higado-no-mejora-mucho-la-prediccion-de-superv-39f08b","titulo":"Medir más tumores en el hígado no mejora mucho la predicción de supervivencia tras el tratamiento","resumen":"Investigadores analizaron tomografías de pacientes con cáncer de hígado tratados con quimioembolización. Compararon predicciones de supervivencia usando una, dos o todas las lesiones medidas, además de variables clínicas básicas, y evaluaron los modelos con datos de otro grupo de pacientes.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Xu, Z., Melek, A., Castillo, E., Wang, H.","url":"https://www.medrxiv.org/content/10.64898/2026.10.28.26366759v1?rss=1","imagen":"/hoy/portada/39f08b7cd8ec9ef4","tema":"salud","subtemas":["cancer de higado","pronostico","tomografia","quimioembolizacion","inteligencia artificial en medicina"],"entidades":["Medical University of Warsaw","WAW-TACE"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-29T00:00:00.000Z","indexTs":"2026-10-30T00:18:54.680Z","hash":"b850aa1d6ea66b17772eb89c69ce9e02c824773a8e396f90bf972510f05f9e1a","tsa":{"time":"Oct 30 00:19:40 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Para un paciente con cáncer de hígado, la pregunta práctica es cuánto tiempo puede esperar y qué tratamiento le conviene. El trabajo sugiere que, en muchos casos, medir cada tumor suma poco frente a los datos clínicos habituales, lo que simplifica el trabajo de los equipos médicos. El estudio es un preprint, todavía sin revisión por pares, y se hizo en una cohorte concreta, así que sus conclusiones necesitan confirmarse en otros hospitales.","quienFirma":"Medical University of Warsaw (WAW-TACE)","confianza":"preprint","consulta":null},"sello":{"hash":"b850aa1d6ea66b17772eb89c69ce9e02c824773a8e396f90bf972510f05f9e1a","sello":"7a1e59e3e4fcbbbe00e5c0b4e541dcf81e5c8a11a2029c86d58fe283b7ce3baf","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6596285,"aleatorio":"c081b28c47de1b3ebaff2ab6fadd94a4e1d5df8956cce1796159e8f3a3c84477","tiempo":"2026-10-30T00:19:30.000Z"},"nist":{"cadena":2,"pulso":2005076,"salida":"D1D471A81853AED712E452A7D73F82257D9E5310F62C5D5691DE99C64EC2110FF870FD06ACCC0EFE8D43CE6737ABC2C8D9860CE82BDD7542A5890EDDB8765434","tiempo":"2026-10-30T00:18:00.000Z"},"noAntes":"2026-10-30T00:19:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 30 00:19:40 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Lesion selection and external evaluation of clinical-imaging survival models after transarterial chemoembolization for hepatocellular carcinoma","descripcion":"Background: Pretreatment computed tomography (CT) describes tumor characteristics in patients receiving transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), but whether measuring more tumors improves mortality predictions in a new cohort remains unclear. We assessed the added value of different lesion-selection scopes beyond shared clinical predictors. Methods: We compared a model using five clinical variables with models adding CT measurements from the largest, two largest, or all retained annotated tumors. All models used the same regularized discrete-time survival estimator. Evaluation used repeated nested cross-validation in 228 WAW-TACE patients and frozen external","pubDate":"2026-10-29","url":"https://www.medrxiv.org/content/10.64898/2026.10.28.26366759v1?rss=1"},"indexado":"2026-10-30T00:18:54.680Z"}}